IMRA America Inc. of Ann Arbor, Mich., and MagArray Inc. of Sunnyvale, Calif., will collaborate to develop MagArray’s magneto-nanoparticle immunoassay technology, which is based on research from Stanford University in California. The companies will develop highly sensitive immunoassay sensor systems. If the work progresses as planned, IMRA will support MagArray’s development with funding of up to $10 million over the next three and a half years. IMRA also will provide scientific and technical support, including nanomaterial technologies. MagArray’s technology could play a leading role in the way that cancer and other serious diseases are diagnosed and treated, said Takashi Omitsu, IMRA’s president.